BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Faron Pharmaceuticals Ltd readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Faron Pharmaceuticals Ltd's drugs
  run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05428969-2934@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bexmarilimab: Phase 1/2 readout est. (NCT05428969)
DESCRIPTION:Bexmarilimab\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A St
 udy to Assess Safety\, Tolerability and Preliminary Efficacy of Bexmarilim
 ab in Combination With Standard of Care in Patients With Hematological Mal
 ignancies\nEstimated primary completion: March 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/bexmarilimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05428969
URL:https://assetmemo.bio/drug/bexmarilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07672769-2934@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Bexmarilimab: Phase 2 readout est. (NCT07672769)
DESCRIPTION:Bexmarilimab\, phase 2\, Higher-Risk Myelodysplastic Syndromes.
 \nStudy: Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Partic
 ipants With Treatment-naïve Higher-risk Myelodysplastic Syndromes\nEstima
 ted primary completion: November 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bexmarilimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07672769
URL:https://assetmemo.bio/drug/bexmarilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
